The chronic leukemias: current and novel therapeutic approaches.
Recent developments with targeted therapies have expanded the therapeutic armamentarium (Table 1) for patients with both CLL and CML. Significant advances in allogeneic and autologous donor transplantation have increased the patient eligibility pool and reduced the toxicities while improving upon long term survival results.
Adele R. Decof Center, Roger Williams Medical Center, 825 Chalkstone Avenue, Providence, RI 02908, USA. rrathore@rwmc.org
Ritesh
R
Rathore
Gerald J
GJ
Elfenbein
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols; D003520:Cyclophosphamide; D004317:Doxorubicin; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000628:therapy*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy*; D011241:Prednisone; D033581:Stem Cell Transplantation; D014750:Vincristine
D000911:Antibodies, Monoclonal; D016898:Interferon-alpha; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone